FKK 01PD
Alternative Names: Apomorphine prodrug - Fabre-Kramer Pharmaceuticals; FKK-01PD; TGHW 01APLatest Information Update: 28 Nov 2025
At a glance
- Originator Fabre-Kramer Pharmaceuticals
- Class Antiparkinsonians; Erectile dysfunction therapies
- Mechanism of Action Dopamine D1 receptor agonists; Dopamine D2 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Erectile dysfunction; Parkinson's disease
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Erectile-dysfunction in USA (PO, Capsule)
- 28 Nov 2025 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO, Capsule)
- 30 Nov 2023 FKK 01PD is still in preclinical development for Parkinson’s disease and Erectile Dysfunction in USA (Fabre-Kramer Pharmaceuticals pipeline, November 2023)